Sterling recognised for exceptional performance with BVCA award

Sterling Pharma Solutions has been recognised by the British Private Equity and Venture Capital Association (BVCA) for its exceptional performance throughout 2021. The award comes as part of the BVCA’s ‘Vision 2022’ initiative to showcase businesses based on growth, competitiveness, innovation, and environmental, social and governance (ESG) factors.

Backed since 2019 by one of BVCA’S private equity and venture capital members, GHO Capital, Sterling has been recognised for its strong organic growth, ESG initiatives and EcoVardis accreditation, and demonstrably placing innovation at the core of its business.

Commenting on the achievement, Kevin Cook, Chief Executive Officer at Sterling said: “2021 was another year of significant growth for Sterling. Each year for the last five years we have achieved growth rates of above 20%. We strongly believe that if we continue to do the right things, we will get the right results. GHO’s continued support has enabled the acquisition of a service and science-focused antibody drug conjugation (ADC) business, further expanding the customer offering for Sterling.

“ESG initiatives remain high on the agenda, with the completion of a combined heat and power plant and the initiation of an anaerobic treatment facility, reducing Sterling’s carbon footprint by 50%. The partnership has delivered on our expectations and more.”

Since 2019, Sterling has focused on reducing its carbon footprint through continued investment into its facilities. This has included the introduction of an anaerobic digestion plant at its Dudley facility to breakdown organic waste into methane gas using anaerobic bacteria, and the organisation is currently working towards the EcoVardis platinum award since achieving its gold rating.

Sterling is on track to complete its acquisition of an 111 acre site in Ringaskiddy, Ireland in early 2023, demonstrating its continued dedication to growth and competitiveness within the industry.